333 related articles for article (PubMed ID: 21881697)
21. [What is better here: ACE inhibitor or AT1 blocker?].
MMW Fortschr Med; 2008 Apr; 150(16):16-7. PubMed ID: 18557213
[No Abstract] [Full Text] [Related]
22. [ Therapy of patients at high risk for vascular events: telmisartan, ramipril or a combination? ].
Düsing R; Nitschmann S
Internist (Berl); 2008 Sep; 49(9):1137-40. PubMed ID: 18665340
[No Abstract] [Full Text] [Related]
23. A third amlodipine/ARB combination (Twynsta) for hypertension.
Med Lett Drugs Ther; 2010 Jan; 52(1329):2-3. PubMed ID: 20208469
[No Abstract] [Full Text] [Related]
24. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.
Clase CM; Barzilay J; Gao P; Smyth A; Schmieder RE; Tobe S; Teo KK; Yusuf S; Mann JF
Kidney Int; 2017 Mar; 91(3):683-690. PubMed ID: 27927602
[TBL] [Abstract][Full Text] [Related]
25. Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study.
Ma L; Wang W; Zhao Y; Zhang Y; Deng Q; Liu M; Sun H; Wang J; Liu L
Am J Cardiovasc Drugs; 2012 Apr; 12(2):137-42. PubMed ID: 22329591
[TBL] [Abstract][Full Text] [Related]
26. Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor.
Sleight P
J Hypertens Suppl; 2009 Jul; 27(5):S23-9. PubMed ID: 19587551
[TBL] [Abstract][Full Text] [Related]
27. A new dawn in cardiovascular protection: total cardiovascular risk: rigorous treatment of risk factors. Introduction.
Ritz E; Dahlöf B
Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S1-2. PubMed ID: 18580859
[No Abstract] [Full Text] [Related]
28. [Therapy of hypertension. Lasting organ protection moves into the foreground].
MMW Fortschr Med; 2003 Nov; 145(47):62. PubMed ID: 14738040
[No Abstract] [Full Text] [Related]
29. Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
Cohn JN
Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):526-7. PubMed ID: 18665135
[TBL] [Abstract][Full Text] [Related]
30. Telmisartan, ramipril, or both in patients at high risk for vascular events.
; Yusuf S; Teo KK; Pogue J; Dyal L; Copland I; Schumacher H; Dagenais G; Sleight P; Anderson C
N Engl J Med; 2008 Apr; 358(15):1547-59. PubMed ID: 18378520
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular protection: a breakthrough for high-risk patients?
Ferrari R
J Hypertens Suppl; 2009 Jul; 27(5):S37-40. PubMed ID: 19587554
[TBL] [Abstract][Full Text] [Related]
32. The ONTARGET/TRANSCEND Trial Programme: baseline data.
Sleight P
Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in cardiovascular risk reduction: implications of ONTARGET.
Guthrie R
Clin Cornerstone; 2009; 9 Suppl 3():S18-26. PubMed ID: 19409352
[TBL] [Abstract][Full Text] [Related]
34. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials.
Williams B; Lacourcière Y; Schumacher H; Gosse P; Neutel JM
J Hum Hypertens; 2009 Sep; 23(9):610-9. PubMed ID: 19225530
[TBL] [Abstract][Full Text] [Related]
35. Early and effective treatment of hypertension: ONTARGET provides some answers.
Cardiovasc J Afr; 2009; 20(5):323. PubMed ID: 19907811
[No Abstract] [Full Text] [Related]
36. Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan.
Volpe M
Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):1061-72. PubMed ID: 23030295
[TBL] [Abstract][Full Text] [Related]
37. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
Schindler C
Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
[TBL] [Abstract][Full Text] [Related]
38. Proteinuria: Is the ONTARGET renal substudy actually off target?
Ruggenenti P; Remuzzi G
Nat Rev Nephrol; 2009 Aug; 5(8):436-7. PubMed ID: 19639016
[No Abstract] [Full Text] [Related]
39. An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors.
Kjeldsen S; Mancia G; Schmieder R; Mattheus M; Unger T
Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):673-82. PubMed ID: 23750676
[TBL] [Abstract][Full Text] [Related]
40. Telmisartan, ramipril, or both in patients at high risk of vascular events.
Büchner N; Banas B; Krämer BK
N Engl J Med; 2008 Jul; 359(4):426. PubMed ID: 18650521
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
